KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Title:
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
Author:
Swords, Ronan T. Greenberg, Peter L. Wei, Andrew H. Durrant, Simon Advani, Anjali S. Hertzberg, Mark S. Lewis, Ian D. Rivera, Gabriel Gratzinger, Dita Fan, Alice C. Felsher, Dean W. Cortes, Jorge E. Watts, Justin M. Yarranton, Geoff T. Walling, Jackie M. Lancet, Jeffrey E.